Triptorelin Extended-Release Suspension (Triptodur®)

Triptodur (triptorelin ER) is covered for FDA‑approved central precocious puberty in pediatric patients ≥2 years and for compendial off‑label use in gender‑dysphoric/gender‑incongruent individuals or those undergoing gender reassignment; uses outside these indications or that do not meet coverage/safety criteria are excluded. Approval requires documentation of the diagnosis, adherence to coverage and applicable safety criteria, specialist prescribing/consultation (endocrinologist or transgender‑care specialist) for transgender‑related use, dosing of 22.5 mg IM every 24 weeks, and is authorized for up to 12 months.

"FDA-approved indication: Triptodur is indicated for the treatment of pediatric patients 2 years of age and older with central precocious puberty (CPP)."

Sign up to see full coverage criteria, indications, and limitations.